All News
Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are at⬆️risk of SARS-CoV-2 infection and⬆️mortality from COVID-19. Abstr#0086 #ACR21 @RheumNow #ACRBest https://t.co/B7tWs02gfc
Richard Conway RichardPAConway ( View Tweet)
Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
Richard Conway RichardPAConway ( View Tweet)
Important differences between vascular pathologies seen in #COVID19 and DIC by Dr. D McGonagle
👉Fibrinogen - normal/sl. ⬆ in PIC-assoc'd COVID19 vs. ⬇ in DIC sec to MAS
@RheumNow #ACR21 #MedTwitter
📌https://t.co/DdmAhVIR51 https://t.co/Xw8LKaKcFd
Links:
sheila RHEUMarampa ( View Tweet)
CARRA survey in SAID pts reported no change in flare frequency w/ COVID19 but many had reduced intensity of fevers during flares. Majority of pts reported mild to moderate symptoms w/ 1/3 had lingering COVID19 symptoms. Abs 1083 #RheumNow #ACR21 @RheumNow https://t.co/qbfsqvXutt https://t.co/6u33VDIexY
Dr. Rachel Tate uptoTate ( View Tweet)
"CH COVID-19: Office Hours: COVID-19 Vaccine in Immune-mediated Inflammatory Disease (IMID) Patients" #ACR21
A great thing about @ACRheum's Convergence is being able to listen to conversations about important topics like booster type & timing specifically for #rhum patients https://t.co/horwWeAen7
International Foundation AiArthritis IFAiArthritis ( View Tweet)
#ACR21
#SLE #COVID19
Use of Telemedicine for follow-up of SLE in COVID19
Wait times lower for telemedicine
Patient satisfaction higher in telemedicine group
More hospitalization, higher switch to in person follow up in telemedicine https://t.co/Y21Vki1uDP
Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)
Join us now at the #ACR21 #COVID19 community hub to hear Kevin Winthrop and @RADoctor discussing about vaccines in patients with RMDs
#ACRAmbassador https://t.co/LivAoLu810
Alessia Alunno alessia_alunno ( View Tweet)
COVID in Rheumatologic Disease Patients: Drs. Sparks, Liew, Yazdany and Dao provide an update on data specific to COVID in rheumatologic disease patients.
@jeffsparks @drdavidliew @KDAO2011
#ACR21
https://t.co/IzDIpe5IrU https://t.co/6i8C3Grw9q
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR21 Ab#1445. RTX & #covid19 outcomes
⭐️RTX ass. w/ Upwards arrow COVID hospitalization, ICU admission, and ventilation
▶️We need huge caution in pts that have not been vax'ed before RTX 💉💉
@Rheumnow
https://t.co/6UNUVhnBkI https://t.co/vHkQe9fZpI
Links:
Eric Dein ericdeinmd ( View Tweet)
@NamrataRheum on outcomes in RA patients on RTX who get COVID-19. ⬆️hospitalisation, ICU, mech ventilation, but not mortality (in this cohort) Abstr#1445 #ACR21 @RheumNow https://t.co/8RcrzTdEb0
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Ab#1445. RTX & #covid19 outcomes
⭐️RTX ass. w/ ⬆️ COVID hospitalization, ICU admission, and ventilation
▶️ We need huge caution in pts that have not been vax'ed before RTX 💉💉
@Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/R7jNb066m6
Links:
Eric Dein ericdeinmd ( View Tweet)
Yup, another large database shows more #hospitalizations with #RheumatoidArthritis with #rituximab but NOT higher mortality in matched analysis. Abst#1445 #ACR21 @RheumNow https://t.co/9XV8iX10sA
Janet Pope Janetbirdope ( View Tweet)
Are you using less #rituximab in #SLE during #COVID #ACR21 @RheumNow #Lupus hub
Janet Pope Janetbirdope ( View Tweet)
"Baseline and routine EKGS are NOT required for SLE patients just because they are on HCQ!" - Dr. HM Belmont. "The drug has been demonized due to its use in COVID patients. We don't need to hold HCQ for EMR alerts (e.g, with cipro, SSRIs, etc)." Abstr#1743 #ACR21 @rheumnow https://t.co/5Bxavo6dRg
TheDaoIndex KDAO2011 ( View Tweet)
Anti-NETs antibodies in #COVID.
1️⃣ correlate➖ w/ SpO2/FiO2 ratio (IgG r=-0.17 IgM r=-0.30
2️⃣correlate➕ w/ ⬆️D-dimer (IgG r=0.33 IgM r=0.19
3️⃣ ⬆️ in pts requiring MV
In a study of 328 pts. Probably driving complement activation!
#ACR21 #Abst1430 @RheumNow https://t.co/2MCrLueTzN
Aurelie Najm AurelieRheumo ( View Tweet)
Abst 1550 #acr21 @RheumNow @bryan_neel rheum pts after covid 19 vaccine: 18.9% reported SEs after the 1st dose,33.1% after 2nd dose. most frequent SEs fever, HA, fatigue & arthromyalgia. All mild&self resolved. Disease flare in 1/180 pts (0.6%) 1st dose 4/118 (3.4%) 2nd dose https://t.co/5AB5CJfYt8
Olga Petryna DrPetryna ( View Tweet)
FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19:
1. RECOVERY - lower mortality
2. EMPACTA - Less progression to mech vent or death
3. REMDACTA & COVACTA - did not meet primary endpoints (but not contradictory) FDA Metanalysis of all 4 trials #ACR21 EUA 6/21 https://t.co/9yHu87KGej
Dr. John Cush RheumNow ( View Tweet)
FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showing it does not need to be given with Remdesivir (4 mg qd maz 14days) #ACR21 https://t.co/r6crPtu3ZH
Dr. John Cush RheumNow ( View Tweet)
FDA Update at #ACR21, Dr. Golding reviews the criteria for EUA - Emergency use authorization for new drugs (critically important during COVID-19) Session 8M115 https://t.co/DqmxEIdvWZ D https://t.co/6aQG8yP7RW
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR21 #Abstr1420 A study checking #COVID vaccine response in 90 #lupus pts and 20 HC:
⬇️Titres of Abs in SLE vs controls
💠Factors of poor response: On any DMARDs exc HCQ only (OR 15) and normal dsDNA
📢Important to pause DMARDs in stable SLE @RheumNow https://t.co/USovFkiCRb https://t.co/bn5CC0xRS9
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)